Proceeds to support ongoing Phase 3 registration trial of Talaris’ lead product candidate FCR001 in living donor kidney transplant, and additional Phase 2 trials next year in autoimmune disease and organ transplant
Financing co-led by Surveyor Capital (a Citadel company) and Viking Global Investors, with multiple new investors participating –
BOSTON, Mass., and LOUISVILLE, Ky., October 6, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, announced the closing of a $115 million Series B financing co-led by Surveyor Capital (a Citadel company) and Viking Global Investors.
Other participants in the financing included new investors Cormorant Asset Management, Invus, funds and accounts managed by BlackRock, Eventide Asset Management, Logos Capital, Aisling Capital and Pamoja Capital, as well as Talaris’ Series A investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.
“Over the past 18 months, Talaris has made dramatic progress in assessing the potential of our unique cell therapy across multiple therapeutic areas. We have initiated a pivotal trial for our lead indication in living donor kidney transplant, laid the groundwork for two additional Phase 2 studies, greatly expanded our team and bolstered our wholly in-house cell processing capabilities,” said Scott Requadt, Chief Executive Officer of Talaris. “We are grateful for the support of this outstanding syndicate of investors to help us advance our immune tolerance programs through important clinical milestones in both organ transplant and autoimmune disease.”
The financing will support the ongoing Phase 3 trial of Talaris’ lead candidate, FCR001, which is now enrolling first-time living donor kidney transplant recipients at sites across the U.S. Additionally, the funds will advance a planned Phase 2 trial of FCR001 in diffuse systemic sclerosis (SSc), a severe form of the rare autoimmune disease scleroderma, as well as a future Phase 2 trial of FCR001 in individuals who have previously received a living donor kidney transplant.
“With this financing Talaris has assembled a world-class investor syndicate that shares our vision of the transformative potential of durable, drug-free immune tolerance,” said Francois Nader, M.D., Chairman of the Board. “We believe Talaris’ therapy could represent a paradigm shift across multiple therapeutic areas.”
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Talaris is backed by a number of leading life sciences investors and maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky. www.TalarisTx.com .
Ten Bridge Communications